Pharmaceuticals, Biotechnology and Life Sciences
Shinogis’ Fetcroja (cefiderocol) has received European Commission (EC) marketing authorisation for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options.
Shinogoi might have cefiderocol approved by the US FDA, as the Advisory Committee reccomends it for treatment of complicated urinary…
Shionogi has reported positive Results from Cefiderocol Phase III study in adults with nosocomial pneumonia caused by gram-negative pathogens, as cefiderocol met primary endpoint of non-inferiority in 14-day all-cause mortality compared to high-dose meropenem.
OSAKA, Japan & AMSTERDAM, NL–(BUSINESS WIRE)–Shionogi & Co., Ltd (hereafter “Shionogi”) announces that the Marketing Authorisation Application (MAA) submission for…